Clinical Trial Search

Primary: Reconnection of Pulmonary Vein Electrogram After Adenosine Infusion — 92 participants

Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event During the Study (Maximum 40 Days) — 20; 19; 21; 20 Participants

Primary: Number of Patients With Drug-related Adverse Events — 12; 13 participants

Primary: Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period — 2.15; 1.80; 1.96; 1.70 seizures per week — p==0.025

Primary: Percent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4) — 17.45; -4.60; 12.34 Percent…

Primary: Successful Device Placement — 10 participants

Primary: Point Accuracy — 83.8 percentage of glucose results in zone A

Primary: Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions — 110531; 95140 #copies/100000 copies housekeeping gene

Primary: Serum Cidal Activity as Tested Against Staphylococcus Aureus Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) — 2; 4; 1; 1 Log inhibition

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12) — 99.1; 98.0 Percentage of participants — p=0.001

Primary: Maximal Plasma Concentration (Cmax) of AGN-223575 — 0.186; 0.128; 0.114; NA Nanograms/Milliliters (ng/mL)

Primary: Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12) — 82.6; 96.8 Percentage of participants

Primary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of Treatment (SVR12) — 94.6 Percentage of participants — p=<0.001

Primary: Duration of Analgesia — 19.1; 19.6; 11.8 hours

Primary: Percentage of Participants Maintaining Their Mean Hemoglobin Concentration Within Plus or Minus 1 Gram/Deciliter of Their Reference Hemoglobin and Between the Target…